Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

BeiGene lung cancer treatment meets main goal in late-stage study

FILE PHOTO: People enter a building of biotechnology firm BeiGene Ltd at the Suzhou Industrial Park in Suzhou, Jiangsu province, China November 22, 2019. Picture taken November 22, 2019. REUTERS/Stringer

BeiGene Ltd said on Tuesday its cancer therapy combination for treating lung cancer in previously untreated patients met the main goal in a late-stage study.

The therapy, tislelizumab, when administered in combination with chemotherapy helped reduce the risk of cancer progression in patients with squamous non-small cell lung cancer.

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shounak Dasgupta)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.